Current Neuro-Oncology

Volume 27 Number 30
31 October 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 30, 31 October

Levine AB, Bennett J, Patil P, Burns I, Siddaway R, Li C, Haizel-Cobbina J, Rana M, Yuditskiy R, Son A, Nakano Y, Patel P, Ho IC, Ku M, Lyons AT, Velázquez Vega JE, Schniederjan MJ, Erker C, Cacciotti C, Santi M, Nelson EJ, Cheng S, Dunham C, Wilson B, Black K, Van Landeghem F, Nobre L, Eisenstat DD, Stücklin ASG, Weiser A, Larouche V, Giannakouros P, Fonseca A, Williamson L, Fernandes IL, Plant-Fox AS, Fleming A, Campbell S, Mushtaq N, Bukhari SI, Minhas K, Graham RT, Raskin S, Jadrijevic-Cvrlje F, Ludlow L, Macneil MV, Mulcahy-Levy JM, Demarsh S, Fukuoka K, Yamasaki K, Suzuki T, Ohka F, Kawamura A, Arakawa Y, Ishihara T, Yamasaki F, Hansford JR, Luck A, Nasrallah MP, Toledano H, Masoud RM, Lassaletta A, Blasco-Santana L, Kilday JP, Talianski A, Davies C, Johnston J, Hale AT, Dirks PB, Rutka JT, Dewan MC, Tabori U, Hawkins CE.
Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma.
Neuro Oncol. 2025 Oct 21:noaf245. doi: 10.1093/neuonc/noaf245. PMID: 41117845. Observational study˰ ˍ

Wang MH, Zhang J, Yang L, Zhao J, Yao H, Xu H, Wu G, Hu J.
Development and validation of a multi-parameter nomogram for venous thromboembolism in patients undergoing surgery for brain tumors: a retrospective analysis.
Neurosurg Rev. 2025 Oct 21;48(1):727. doi: 10.1007/s10143-025-03887-2. PMID: 41117840. Observational study˰ ˍ

Cheng C, Zhao C, Liang B, Sun Y, Zhao D, Ma P, Wang C, Wang D, Pan C, Zhai Y, Yu M, Zhang Z, Li G, Jiang T, Zhang W.
Strategy and clinical benefit of first re-resection for recurrent adult-type diffuse glioma: A retrospective cohort analysis.
Med. 2025 Oct 22:100891. doi: 10.1016/j.medj.2025.100891. PMID: 41130212. Observational study˰ ˍ

*Xu L, Yu D, Li F, Ding X, Cao Y.
A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center.
BMC Cancer. 2025 Oct 22;25(1):1623. doi: 10.1186/s12885-025-15123-7. PMID: 41126110. Observational study. ˍ

Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M.
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8⁺ infiltration in glioma.
Sci Rep. 2025 Oct 23;15(1):37112. doi: 10.1038/s41598-025-21064-9. PMID: 41131134. Interventional study. ˍ

Bessette J, Arditi J, Noreck J, Edwards R, Kaiserman J, Wortelboer R, Nguyen MA, Siwik W, Gautam S, Szymanski T, Wong ET.
Medical comorbidities prognosticate survival in glioblastoma.
BJC Rep. 2025 Oct 24;3(1):75. doi: 10.1038/s44276-025-00189-4. PMID: 41136649. Observational study. ˍ

Ghalibafian M, Mirzaei S, Sadeghi Y, Afsar N, Yeganeh SH, Tasbihi M, Ashrafi M, Lahijani NJ, Bouffet E.
Diffuse pontine glioma (DPG): shorter or longer treatment time?
J Neurooncol. 2025 Oct 24;176(1):40. doi: 10.1007/s11060-025-05308-2. PMID: 41134453. Observational study˰ ˍ

Hoosemans LJN, Panayotopoulos LF, van Kuijk SMJ, Verduin M, Anten MHME, Pasmans RCOS, Schellekens JM, Huijs SMH, Verhoeff SR, van den Berkmortel FWPJ, Steggink LC, Ackermans L, Schijns OEMG, Teernstra OPM, Hovinga K, Beckervordersandforth JC, Compter I, Eekers DBP, Postma AA, Vooijs MA, Broen MPG, Hoeben A.
Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis.
J Neurooncol. 2025 Oct 24;176(1):42. doi: 10.1007/s11060-025-05299-0. PMID: 41134378. Observational study. ˍ

Lin T, Ke S, Hu C, Assadi R, Huang J, Gupta S, Rawojc K, Kleinberg L, Mukherjee D, Rincon-Torroella J, Weingart JD, Holdoff M, Grossman S, Ahmed MM, Redmond KJ.
Low Dose Fractionated Radiation Therapy As a Chemo-Potentiator of Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma: A Single-Arm Phase I/II Trial.
Int J Radiat Oncol Biol Phys. 2025 Oct 24:S0360-3016(25)06396-5. doi: 10.1016/j.ijrobp.2025.10.014. PMID: 41138784. Interventional study˰ ˍ

Smith AKS, Dhanda SK, Billups CA, Sioson E, Lu C, Peraza AZ, Gangwani K, Li Y, Li Q, Lin T, Michalski JM, Packer RJ, Olson JM, Leary SES, Fouladi M, Gajjar A, Zhou X, Onar-Thomas A, Northcott PA, Robinson GW.
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival.
Neuro Oncol. 2025 Oct 24:noaf250. doi: 10.1093/neuonc/noaf250. PMID: 41159377. Interventional study. ˍ

Tang LK, Sun Y, Zhang MH, Jiang H, Li ZK, Du GB.
Combined temozolomide, immunotherapy and radiotherapy in a patient with anaplastic oligodendroglioma and multiple extracranial metastases: A rare case report.
Medicine (Baltimore). 2025 Oct 24;104(43):e45142. doi: 10.1097/MD.0000000000045142. PMID: 41137316Case report. ˍ

Wang X, Zuo Z, Yu S, Lin S, Yu T.
Long-term clinical prognosis of patients with gliomas infiltrating corticospinal tract on DTI tractography.
Chin Neurosurg J. 2025 Oct 24;11(1):26. doi: 10.1186/s41016-025-00412-8. PMID: 41137160. Observational study. ˍ

Nguyen MK, Jelinek M, Singh A, Isett B, Myers ES, Mullett SJ, Eisele Y, Beumer JH, Parise RA, Urban J, Rose A, Sellitto L, Singh K, Doerfler R, Dadey RE, Kim C, Rhee JC, Davar D, Villaruz LC, Burgess M, Drappatz J, Mantica M, Goodman AE, Wang H, Singhi AD, Luke JJ, Zandberg DP, Bao R.
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
Oncologist. 2025 Oct 25:oyaf362. doi: 10.1093/oncolo/oyaf362. PMID: 41138165. Interventional study. ˍ

Teske N, Dono A, Young JS, Juenger ST, Youssef GC, Häni L, Sciortino T, Bruno F, Dietrich J, Mau CY, Weller M, Beck J, Hervey-Jumper S, Molinaro AM, Chang SM, van den Bent M, Vogelbaum MA, Ruge MI, Cahill DP, Rudà R, Bello L, Grau SJ, Schnell O, Huang RY, Wen PY, Tandon N, Berger MS, Tonn JC, Esquenazi Y, Karschnia P.
Associations of supramaximal resection with outcome in glioblastoma across age groups: a report of the RANO resect group.
Neuro Oncol. 2025 Oct 25:noaf239. doi: 10.1093/neuonc/noaf239. PMID: 41137668. Observational study˰ ˍ

Bartsch R, Marhold M, Garde-Noguera J, Gion M, Ruiz-Borrego M, Greil R, Valero M, Llombart-Cussac A, García-Mosquera JJ, Arumi M, Cortés J, Campolier M, Guerrero JA, Slebe F, Martínez-García E, Jiménez-Cortegana C, Vaz-Batista M, Oberndorfer F, Furtner J, Fuereder T, Berghoff AS, Preusser M.
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2025 Oct 27;26(11):1467-1478. doi: 10.1016/S1470-2045(25)00470-X. PMID: 41167215. Interventional study˰

Bergman L, Agur A, Gabay S, Tankus A, Strauss I, Zach L, Aizenstein O, Grossman R, Shahar T, Strauss I.
Imaging changes and Clinical outcome after MR-guided Laser Interstitial Thermal Therapy.
Stereotact Funct Neurosurg. 2025 Oct 27:1-23. doi: 10.1159/000549229. PMID: 41144626. Observational study. ˍ

Fuereder T, Garde-Noguera J, García-Mosquera JJ, Ruiz-Borrego M, Valero M, Llombart-Cussac A, Gion M, Greil R, Arumi M, Campolier M, Guerrero JA, Raimondi G, Mancino M, Jiménez-Cortegana C, Vaz-Batista M, Oberndorfer F, Marhold M, Berghoff AS, Furtner J, Bartsch R, Preusser M.
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2025 Oct 27;26(11):1454-1466. doi: 10.1016/S1470-2045(25)00465-6. PMID: 41167214. Interventional study˰ ˍ

Sun Y, Hamo M, Atchley T, Markert JM, Nabors B, Estevez-Ordonez D.
Survival outcomes associated with antidepressant use in glioblastoma: a cohort study.
J Neurooncol. 2025 Oct 27;176(1):47. doi: 10.1007/s11060-025-05288-3. PMID: 41144062. Observational study. ˍ

Zhang G, Zhou H, Han W, Lou L, Xue X.
Prognostic modeling for diffuse midline glioma: development and validation of a risk stratification nomogram using SEER and institutional cohorts.
Front Oncol. 2025 Oct 27;15:1644388. doi: 10.3389/fonc.2025.1644388. PMID: 41220938. Observational study. ˍ

Yoshioka M, Noguchi S, Iwadate Y, Kobayashi M, Motohashi S, Higuchi Y.
MGMT Promoter Methylation in Glioblastoma Stem Cells: Stability During Differentiation and Comparison With Surgically-resected Tumors.
Anticancer Res. 2025 Oct 28;45(11):4959-4969. doi: 10.21873/anticanres.17839. PMID: 41151883. Laboratory investigation˰ ˍ

Cloughesy TF, van den Bent MJ, Touat M, Blumenthal DT, Peters KB, Ellingson BM, Clarke JL, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry J, Giglio P, de la Fuente M, Maher E, Bottomley A, Tron AE, Yi D, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Mellinghoff IK; INDIGO trial investigators.
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2025 Oct 29:S1470-2045(25)00472-3. doi: 10.1016/S1470-2045(25)00472-3. PMID: 41175888. Interventional study˰ ˍ

Del Baldo G, Di Ruscio V, Cacchione A, Lo Sasso A, Corvino L, D'Orazio C, De Salvo A, Albino G, Cipri S, Miele E, Giovannoni I, Rossi S, Colafati GS, Vennarini S, Carai A, Mastronuzzi A.
Clinical, toxicity and long-term neurocognitive outcomes of first-line intensive chemotherapy in infant medulloblastoma: a single-center cohort study following AIEOP recommendations.
J Neurooncol. 2025 Oct 29;176(1):54. doi: 10.1007/s11060-025-05301-9. PMID: 41160229. Observational study. ˍ

Huang B, Liu T, Li H, Li X, Lu G, Li J.
Epidemiological characteristics and prognostic factors of high-grade brainstem glioma for all ages and the establishment of a nomogram.
Transl Cancer Res. 2025 Oct 29;14(10):7186-7198. doi: 10.21037/tcr-2025-1030. PMID: 41234848. Observational study. ˍ

Wu Y, Ren Y, Li S, Zeng M, Wang J, Li M, Peng Y.
Association between intraoperative hypotension during brain tumor resection and postoperative delirium: A secondary analysis of a randomized controlled trial.
PLoS One. 2025 Oct 29;20(10):e0334094. doi: 10.1371/journal.pone.0334094. PMID: 41160633. Interventional study. ˍ

Bilski M, Noël G, Smółka K, Kuncewicz K, Kuźnicki W, Feuvret L, Korab K, Peszyńska-Piorun M, Korona P, Baranowska I, Suleja A, Le Fevre C, Schott R, Somme L, Chabli S, Mesny E, Mastroleo F, Kotecha R, Jurkiewicz J, Fijuth J, Jereczek-Fossa BA, Krystkiewicz K, Harat M, Kuncman Ł.
Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy.
Sci Rep. 2025 Oct 30;15(1):38011. doi: 10.1038/s41598-025-21934-2. PMID: 41168285. Observational study. ˍ

Padilla O, Tazhibi M, McQuillan N, Buss EJ, Sisti MB, Bruce JN, McKhann GM, Cheng SK, Wang TJC.
Sex-Based Differences in Outcomes for Glioblastoma Patients Treated with Hypofractionated Chemoradiotherapy.
Cancers (Basel). 2025 Oct 30;17(21):3486. doi: 10.3390/cancers17213486. PMID: 41228279. Observational study. ˍ

Wang J, Niu X, Chang T, Quan Y, Mwibwe LM, Liu Y, Wang X, Yang Y, Mao Q.
The impact of maximized resection and standardized systemic therapy on overall survival in adult patients with thalamic gliomas.
Front Oncol. 2025 Oct 30;15:1681695. doi: 10.3389/fonc.2025.1681695. PMID: 41244892. Observational study. ˍ

Yamada K, Matsuda R, Sasaki R, Maeoka R, Nakazawa T, Morimoto T, Morisaki Y, Yokoyama S, Kotsugi M, Takeshima Y, Yamada S, Nishimura F, Park YS, Nakagawa I.
Postoperative Seizures Can Predict Overall Survival of Patients With Newly Diagnosed Supratentorial Isocitrate Dehydrogenase-Wild Glioblastoma Treated With Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
Brain Tumor Res Treat. 2025 Oct 31;13(4):140-146. doi: 10.14791/btrt.2025.0022. PMID: 41218815. Observational study. ˍ